This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dorssers, L. C. J. Articles by Sweep, F. C. G. J. Search for Related Content PubMed PubMed Citation Articles by Dorssers, L. C. J. Articles by Sweep, F. C. G. J.

The Prognostic Value of BCAR1 in Patients with Primary Breast Cancer

¹ Department of Pathology, Division of Molecular Biology, Erasmus MC Rotterdam, Rotterdam; ² Department of Chemical Endocrinology, University Medical Center Nijmegen, Nijmegen; and ³ Department of Medical Oncology, Erasmus MC Rotterdam, Rotterdam, the Netherlands

Purpose: BCAR1, the human homologue of the rat p130Cas protein, was identified in a functional screen for human breast cancer cell proliferation resistant to antiestrogen drugs. Here, we study the prognostic value of quantitative BCAR1 levels in a large series of breast cancer specimens.

Experimental Design: A specific ELISA was developed to measure BCAR1 protein levels in 2593 primary breast tumor cytosols. Tumor levels of BCAR1 were correlated with relapse-free survival (RFS) and overall survival (OS) and compared with collected data on urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1).

Results: In tumor cytosols, BCAR1 protein levels varied between 0.02 and 23 ng/mg protein. BCAR1 levels exhibited a positive correlation with steroid hormone receptor levels, age and menopausal status, and uPA and PAI-1 levels. The level of BCAR1 (continuous or categorized as low, intermediate, or high) was inversely related with RFS and OS time. Multivariate analysis showed that BCAR1 levels contributed independently to a base model containing the traditional prognostic factors for both RFS and OS (both P < 0.0001). When added together with uPA and PAI-1 in the multivariate model, BCAR1 contributed independently of PAI-1 and was favored over uPA. Interaction tests allowed for additional analyses of BCAR1 protein levels in clinically relevant subgroups stratified by nodal and menopausal status.

Conclusions: The quantitative BCAR1 protein level represents a prognostic factor for RFS and OS in primary breast cancer, independent of the traditional prognostic factors and the other novel marker PAI-1.

This article has been cited by other articles:

				R. B. Riggins, K. S. Thomas, H. Q. Ta, J. Wen, R. J. Davis, N. R. Schuh, S. S. Donelan, K. A. Owen, M. A. Gibson, M. A. Shupnik, et al. Physical and Functional Interactions between Cas and c-Src Induce Tamoxifen Resistance of Breast Cancer Cells through Pathways Involving Epidermal Growth Factor Receptor and Signal Transducer and Activator of Transcription 5b. Cancer Res., July 15, 2006; 66(14): 7007 - 7015. [Abstract] [Full Text] [PDF]

				D. Meijer, T. van Agthoven, P. T. Bosma, K. Nooter, and L. C.J. Dorssers Functional Screen for Genes Responsible for Tamoxifen Resistance in Human Breast Cancer Cells Mol. Cancer Res., June 1, 2006; 4(6): 379 - 386. [Abstract] [Full Text] [PDF]

				Y. Shen, Z. Jia, R. G. Nagele, H. Ichikawa, and G. S. Goldberg Src Uses Cas to Suppress Fhl1 in Order to Promote Nonanchored Growth and Migration of Tumor Cells Cancer Res., February 1, 2006; 66(3): 1543 - 1552. [Abstract] [Full Text] [PDF]

				J. Brabek, S. S. Constancio, P. F. Siesser, N.-Y. Shin, A. Pozzi, and S. K. Hanks Crk-Associated Substrate Tyrosine Phosphorylation Sites Are Critical for Invasion and Metastasis of Src-Transformed Cells Mol. Cancer Res., June 1, 2005; 3(6): 307 - 315. [Abstract] [Full Text] [PDF]